In This Issue/Research Watch/News in Brief/News From the Iaslc Tobacco Control Committee
Rearranging Detection of Gene Rearrangements
FDG-PET/CT as a Predictor of Outcome in EGFR-Mutant Non–Small-Cell Lung Cancer
Pulmonary Large-Cell Neuroendocrine Carcinoma
Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non–Small-Cell Lung Cancer
Crizotinib Associated with Ground-Glass Opacity Predominant Pattern Interstitial Lung Disease
Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung
Folate Receptor–Positive Circulating Tumor Cell Detected by LT-PCR–Based Method as a Diagnostic Biomarker for Non–Small-Cell Lung Cancer
Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non–Small Cell Lung Cancer Xenograft Models
Epigenetic Repression of CCDC37 and MAP1B Links Chronic Obstructive Pulmonary Disease to Lung Cancer
Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non–Small-Cell Lung Cancer with Activating EGFR Mutation
Patterns of Disease Recurrence after SABR for Early Stage Non–Small-Cell Lung Cancer
Outcomes after Stereotactic Body Radiotherapy versus Limited Resection in Older Patients with Early-Stage Lung Cancer
A Predictive Model for Lymph Node Involvement with Malignancy on PET/CT in Non–Small-Cell Lung Cancer
Nomograms Predict Overall Survival for Patients with Small-Cell Lung Cancer Incorporating Pretreatment Peripheral Blood Markers
Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy
A Case of Pulmonary Squamous Cell Carcinoma Revealed Ground Glass Opacity on Computed Tomography
18F-Sodium Fluoride PET–CT for the Assessment of Brain Metastasis from Lung Adenocarcinoma
Dose-Escalated Stereotactic Body Radiotherapy (SBRT) as a Salvage Treatment for Two Cases with Relapsed Peripheral Lung Cancer After Initial SBRT
Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non–Small Cell Lung Cancer Patient
A Case of Squamous Cell Carcinoma Harboring an EML4-ALK Rearrangement that Was Unsuccessfully Treated with the ALK Inhibitor Alectinib
Bevacizumab in Combination with Chemotherapy or Molecularly Targeted Agents for Non–Small-Cell Lung Cancer with Brain Metastases
Incidental Findings Implying an Inherited Cancer Syndrome from Advanced Tumor Sequencing
In Response
Challenges in Bevacizumab and Gefitinib Combination Therapy for Patients with Non–Small-Cell Lung Cancer
Challenges in Bevacizumab and Gefitinib Combination Therapy for Patients with Non–Small-Cell Lung Cancer
Rare versus Artifactual EGFR Mutations
Reply to Rare Versus Artifactual EGFR Mutations
Maintenance Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor after First-Line Chemotherapy in Mutation-Positive Non–Small-Cell Lung Cancer
Reply
Searching for ROS1 Rearrangements in Lung Cancer by Fluorescent In Situ Hybridization
In Response